There are studies that have shown overexpression of IL-6 in inflamed bowel tissues of IBD patients [23,24], and more recently, therapies specifically targeting IL-6 inhibition are in clinical trials [25,26]. This evidence concerns the gene IL6 and inflammatory bowel disease.